SEC Comment Letter 0000000000-24-005323 to Silence Therapeutics plc (SLN, SLNCF) (CIK 0001479615) (SLN)
Silence Therapeutics plc (SLN, SLNCF) (CIK 0001479615)
Date: May 10, 2024 · CIK: 0001479615 · Accession: 0000000000-24-005323
AI Filing Summary & Sentiment
File numbers found in text: 333-279185
Letter
United States securities and exchange commission logo May 10, 2024 Craig Tooman President and Chief Executive Officer Silence Therapeutics plc 72 Hammersmith Road London W14 8TH United Kingdom Re:Silence Therapeutics plc Registration Statement on Form F-3 Filed May 7, 2024 File No. 333-279185 Dear Craig Tooman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
May 10, 2024
Craig Tooman
President and Chief Executive Officer
Silence Therapeutics plc
72 Hammersmith Road
London W14 8TH
United Kingdom
Re:Silence Therapeutics plc
Registration Statement on Form F-3
Filed May 7, 2024
File No. 333-279185
Dear Craig Tooman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences